Vaccine Progress and Whats Next
Salveen Richter, lead analyst for the US Biotechnology sector\xa0in Goldman Sachs Research, talks about Pfizer\u2019s clinical-trial results for its COVID-19 vaccine and the obstacles that still lie ahead for FDA approval and widespread distribution.